Glenview Trust’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $173M | Sell |
188,371
-1,448
| -0.8% | -$1.47M | 2.72% | 6 |
|
|
2025
Q4 | $204M | Sell |
189,819
-993
| -0.5% | -$949K | 3.15% | 6 |
|
|
2025
Q3 | $146M | Buy |
190,812
+536
| +0.3% | +$399K | 2.31% | 8 |
|
|
2025
Q2 | $148M | Buy |
190,276
+1,165
| +0.6% | +$905K | 2.57% | 5 |
|
|
2025
Q1 | $156M | Sell |
189,111
-1,360
| -0.7% | -$1.13M | 3.03% | 5 |
|
|
2024
Q4 | $147M | Buy |
190,471
+424
| +0.2% | +$351K | 2.76% | 5 |
|
|
2024
Q3 | $168M | Sell |
190,047
-3,059
| -2% | -$2.75M | 3.24% | 5 |
|
|
2024
Q2 | $175M | Sell |
193,106
-4,473
| -2% | -$3.58M | 3.52% | 4 |
|
|
2024
Q1 | $154M | Buy |
197,579
+1,100
| +0.6% | +$783K | 3.3% | 4 |
|
|
2023
Q4 | $115M | Sell |
196,479
-1,046
| -0.5% | -$611K | 2.81% | 6 |
|
|
2023
Q3 | $106M | Sell |
197,525
-13,679
| -6% | -$7.05M | 2.93% | 6 |
|
|
2023
Q2 | $99.1M | Sell |
211,204
-21,819
| -9% | -$9.15M | 2.7% | 6 |
|
|
2023
Q1 | $80M | Buy |
233,023
+94,826
| +69% | +$32M | 2.4% | 7 |
|
|
2022
Q4 | $50.6M | Sell |
138,197
-2,361
| -2% | -$837K | 1.68% | 13 |
|
|
2022
Q3 | $45.5M | Sell |
140,558
-2,183
| -2% | -$692K | 1.72% | 10 |
|
|
2022
Q2 | $46.3M | Sell |
142,741
-8,348
| -6% | -$2.51M | 1.7% | 10 |
|
|
2022
Q1 | $43.3M | Buy |
151,089
+4,314
| +3% | +$1.11M | 1.41% | 16 |
|
|
2021
Q4 | $40.5M | Buy |
146,775
+3,616
| +3% | +$917K | 1.34% | 17 |
|
|
2021
Q3 | $33.1M | Buy |
143,159
+3,108
| +2% | +$767K | 1.28% | 17 |
|
|
2021
Q2 | $32.1M | Buy |
140,051
+19,991
| +17% | +$4.02M | 1.24% | 18 |
|
|
2021
Q1 | $22.4M | Buy |
120,060
+47,638
| +66% | +$9.32M | 0.97% | 31 |
|
|
2020
Q4 | $12.2M | Sell |
72,422
-372
| -0.5% | -$55.5K | 0.57% | 60 |
|
|
2020
Q3 | $10.8M | Sell |
72,794
-1,638
| -2% | -$254K | 0.56% | 56 |
|
|
2020
Q2 | $12.2M | Sell |
74,432
-3,115
| -4% | -$478K | 0.7% | 44 |
|
|
2020
Q1 | $10.8M | Buy |
77,547
+72
| +0.1% | +$9.89K | 0.75% | 41 |
|
|
2019
Q4 | $10.2M | Sell |
77,475
-1,498
| -2% | -$174K | 0.57% | 58 |
|
|
2019
Q3 | $8.83M | Buy |
78,973
+2,080
| +3% | +$232K | 0.53% | 61 |
|
|
2019
Q2 | $8.52M | Sell |
76,893
-2,450
| -3% | -$289K | 0.53% | 61 |
|
|
2019
Q1 | $10.3M | Sell |
79,343
-253
| -0.3% | -$30.8K | 0.66% | 47 |
|
|
2018
Q4 | $9.21M | Buy |
79,596
+373
| +0.5% | +$41.7K | 0.68% | 42 |
|
|
2018
Q3 | $8.5M | Sell |
79,223
-115
| -0.1% | -$11.5K | 0.54% | 58 |
|
|
2018
Q2 | $6.77M | Sell |
79,338
-1,787
| -2% | -$147K | 0.5% | 62 |
|
|
2018
Q1 | $6.28M | Sell |
81,125
-1,070
| -1% | -$86.1K | 0.43% | 75 |
|
|
2017
Q4 | $6.94M | Sell |
82,195
-655
| -0.8% | -$55.7K | 0.48% | 72 |
|
|
2017
Q3 | $7.09M | Sell |
82,850
-1,407
| -2% | -$115K | 0.52% | 66 |
|
|
2017
Q2 | $6.93M | Sell |
84,257
-4,151
| -5% | -$339K | 0.54% | 67 |
|
|
2017
Q1 | $7.44M | Sell |
88,408
-4,834
| -5% | -$387K | 0.59% | 57 |
|
|
2016
Q4 | $6.86M | Buy |
+93,242
| New | +$6.94M | 0.57% | 61 |
|
|
2015
Q4 | $8.56M | Buy |
+101,648
| New | +$8.44M | 0.89% | 41 |
|
|
2014
Q4 | $13.5M | Buy |
+195,448
| New | +$13.2M | 1.44% | 20 |
|
|
2013
Q4 | $11.2M | Buy |
+219,652
| New | +$11M | 1.29% | 26 |
|
Other funds holding LLY
VCM
VPM
Glenview Trust's LLY Position: Q1 2026 in Review
Glenview Trust reduced its Eli Lilly (LLY) stake by 0.76% in Q1 2026, selling an estimated $1.47M and leaving 188,371 shares worth $173M. The position accounts for 2.72% of the portfolio, ranked #6.
Glenview Trust first reported a position in LLY in Q4 2013 and has held it in 41 quarters since. The position peaked at $204M in Q4 2025. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.
- Glenview Trust held 188,371 shares of Eli Lilly worth $173M as of Q1 2026.
- Glenview Trust sold 1,448 Eli Lilly shares in Q1 2026, an estimated $1.47M.
- Eli Lilly made up 2.72% of Glenview Trust's portfolio in Q1 2026, its #6 holding.
- Glenview Trust first reported a position in Eli Lilly in Q4 2013 and has held it in 41 quarters since.
- Glenview Trust's Eli Lilly position peaked at $204M in Q4 2025.
- 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.
Based on Glenview Trust's 13F filing for Q1 2026, filed 8 May 2026.